214 related articles for article (PubMed ID: 25694077)
1. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.
Mendonça Júnior FJ; Scotti L; Ishiki H; Botelho SP; Da Silva MS; Scotti MT
Mini Rev Med Chem; 2015; 15(8):630-47. PubMed ID: 25694077
[TBL] [Abstract][Full Text] [Related]
2. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
[TBL] [Abstract][Full Text] [Related]
3. [Olanzapine].
Nagai N; Watanabe K
Nihon Rinsho; 2013 Apr; 71(4):666-72. PubMed ID: 23678597
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Shayegan DK; Stahl SM
CNS Spectr; 2004 Oct; 9(10 Suppl 11):6-14. PubMed ID: 15475871
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
[TBL] [Abstract][Full Text] [Related]
6. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
7. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Shahid M; Walker GB; Zorn SH; Wong EH
J Psychopharmacol; 2009 Jan; 23(1):65-73. PubMed ID: 18308814
[TBL] [Abstract][Full Text] [Related]
8. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine: a basic science update.
Bymaster F; Perry KW; Nelson DL; Wong DT; Rasmussen K; Moore NA; Calligaro DO
Br J Psychiatry Suppl; 1999; (37):36-40. PubMed ID: 10211140
[TBL] [Abstract][Full Text] [Related]
10. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine.
Brea J; Castro M; Loza MI; Masaguer CF; Raviña E; Dezi C; Pastor M; Sanz F; Cabrero-Castel A; Galán-Rodríguez B; Fernández-Espejo E; Maldonado R; Robledo P
Neuropharmacology; 2006 Aug; 51(2):251-62. PubMed ID: 16697427
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics in bipolar depression: potential mechanisms of action.
Yatham LN; Goldstein JM; Vieta E; Bowden CL; Grunze H; Post RM; Suppes T; Calabrese JR
J Clin Psychiatry; 2005; 66 Suppl 5():40-8. PubMed ID: 16038601
[TBL] [Abstract][Full Text] [Related]
12. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system.
Ikegami M; Ikeda H; Ohashi T; Kai M; Osada M; Kamei A; Kamei J
Neuroendocrinology; 2013; 98(3):224-32. PubMed ID: 24135197
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of atypical antipsychotics in depressive syndromes].
Quintin P; Thomas P
Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
[TBL] [Abstract][Full Text] [Related]
15. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Liao Y; Venhuis BJ; Rodenhuis N; Timmerman W; Wikström H; Meier E; Bartoszyk GD; Böttcher H; Seyfried CA; Sundell S
J Med Chem; 1999 Jun; 42(12):2235-44. PubMed ID: 10377229
[TBL] [Abstract][Full Text] [Related]
16. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Zhang JY; Kowal DM; Nawoschik SP; Lou Z; Dunlop J
Biochem Pharmacol; 2006 Feb; 71(4):521-9. PubMed ID: 16336943
[TBL] [Abstract][Full Text] [Related]
17. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.
Kirk SL; Glazebrook J; Grayson B; Neill JC; Reynolds GP
Psychopharmacology (Berl); 2009 Nov; 207(1):119-25. PubMed ID: 19688201
[TBL] [Abstract][Full Text] [Related]
19. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
[TBL] [Abstract][Full Text] [Related]
20. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
